Please assess the completion status of the following clinical trial:

Trial Title: Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone in Elderly Myeloma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* untreated myeloma patients~* age \>65 years of age or younger but excluded from transplant procedure~* Durie \& Salmon stage II or III myeloma and measurable disease.~* Patients agreed to use contraception~Exclusion Criteria:~* other cancer~* psychiatric disease and any grade 2 peripheral neuropathy

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).